U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO COMPLETE IF KNOWN **Application Number** 10/633,742 1253 Confirmation Number INFORMATION DISCLOSURE Filing Date 8/4/2003 STATEMENT BY APPLICANT (use as many sheets as necessary) First Named Inventor Kevin Gene Peters **Group Art Unit Examiner Name** DEC 1 8 2003 SHEET Attorney Docket Number 9045M

NON PATENT LITERATURE DOCUMENTS

EXAMINER	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial,	
INITIALS*	No.1	symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T².
NN	2	WANG, Y. et al., "Expressions and Characterization of Wild Type, Truncated, and Mutant Forms of the	
		Intracellular Region of the Receptor-Like Protein Tyrosine Phosphatase HPTPβ*, The J. of biological	
		<u>Chem.</u> , 1992, Vo. 267, No. 23, pp.	
NN	3	WRIGHT, M.B. et al., "Protein-Tyrosine Phosphatases in the Vessel Wall Differential Expression After Acute	
		Arterial Injury", Arterioscler Thromb Vasc., 2000, pp. 1189-1198.	
NN	4	FACHINGER, G. et al., "Functional Interaction of Vascular Endothelial-Protein-Tyrosine Phosphatase,with	
		the angiopoietin Receptor Tie-2", Oncogene, 1999, Vol. 18, pp. 5948-5953.	
NN	5	GAITS, F. et al., "Increase In Receptor-like Protein tyrosine Phosphatase Activity and Expression Level on	÷
	•	Density-dependent Growth Arrest fo Endothelial Cells", <u>Biochem. J.</u> , 1995, Vol 311, pp. 97-103.	
· NN	6	HARDER, K.W. et al., "Characterization and kinetic analysis of the intracellular domain of human protein	
		tyrosine phosphatase β (ΗΡΤΡβ) using synthetic phosphopeptides", <u>Biochem J.</u> , 1994, Vol. 296, pp. 395-	
		401.	
NN ·	7	KRUEGER, N.X. et al., "Structural diversity and evolution of human receptor-like protein tyrosine	
		phosphatases", <u>The EMBRO J.</u> , 1990, Vol 9, No. 10, pp. 3241-3252.	•:
	· .		
•	:	^	
EXAMINER	ł ·	/Nashaat Nashed/ (04/25/2006)	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003)